These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10723239)

  • 1. [A randomized trial of conventional dose vs reduced dose in BHAC-DM therapy for acute myelogenous leukemia in elderly patients].
    Mori M; Nisimura H; Urabe A; Tamura K; Makino S; Okabe K; Tomiyama J; Hara M; Tanimoto M; Kikuchi M; Hamaguchi H; Sato H; Saburi Y
    Rinsho Ketsueki; 2000 Feb; 41(2):109-14. PubMed ID: 10723239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.
    Miyawaki S; Tanimoto M; Kobayashi T; Minami S; Tamura J; Omoto E; Kuriyama K; Hatake K; Saito K; Kanamaru A; Oh H; Ohtake S; Asou N; Sakamaki H; Yamada O; Jinnai I; Tsubaki K; Takeyama K; Hiraoka A; Matsuda S; Takahashi M; Shimazaki C; Adachi K; Kageyama S; Ohno R
    Int J Hematol; 1999 Aug; 70(2):97-104. PubMed ID: 10497848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG).
    Ohno R; Kobayashi T; Morishima Y; Hiraoka A; Imai K; Asoh N; Tsubaki K; Tomonaga M; Takahashi I; Kodera K
    Leukemia; 1992; 6 Suppl 2():92-5. PubMed ID: 1578954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cancer curable by chemotherapy: acute myelogenous leukemia].
    Ohno R; Tanimoto M; Morishita Y; Morishima Y; Saito H; Yokomaku S; Nagai T; Kodera Y; Minami S
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1329-34. PubMed ID: 2730046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].
    Fujiwara M; Satou N; Izumi N; Shibasaki Y; Higashimura M; Tsukada N; Koike T
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1793-8. PubMed ID: 18030012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.
    Kobayashi T; Miyawaki S; Tanimoto M; Kuriyama K; Murakami H; Yoshida M; Minami S; Minato K; Tsubaki K; Ohmoto E; Oh H; Jinnai I; Sakamaki H; Hiraoka A; Kanamaru A; Takahashi I; Saito K; Naoe T; Yamada O; Asou N; Kageyama S; Emi N; Matsuoka A; Tomonaga M; Ohno R
    J Clin Oncol; 1996 Jan; 14(1):204-13. PubMed ID: 8558199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
    Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
    Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
    Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
    Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy for minimally differentiated acute myeloid leukemia (AML-M0). A report on five cases and review of the literature.
    Yokose N; Ogata K; Ito T; Miyake K; An E; Inokuchi K; Yamada T; Gomi S; Tanabe Y; Ohki I
    Ann Hematol; 1993 Feb; 66(2):67-70. PubMed ID: 8383541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chronic myelocytic leukemia following chemotherapy of acute promyelocytic leukemia].
    Sakamaki H; Nakamura S; Maruyama Y; Nagata K; Yahara Y; Onozawa Y
    Rinsho Ketsueki; 1989 Nov; 30(11):1975-81. PubMed ID: 2691721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of acute nonlymphocytic leukemia with leukemic cell infiltration to the uterus followed by bone marrow relapse].
    Shiga Y; Shichishima T; Aikawa K; Gotoh J; Furukawa T; Yamagiwa A; Ishibashi T; Maruyama Y
    Rinsho Ketsueki; 1994 May; 35(5):501-5. PubMed ID: 8028198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
    Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
    Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia].
    Taguchi H; Kubonishi I; Takehara N; Uemura Y; Iwahara Y; Eguchi T; Miyagi T; Sugito S; Muneishi H; Tanaka Y
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1309-14. PubMed ID: 1503485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.
    Vogler WR; Velez-Garcia E; Weiner RS; Flaum MA; Bartolucci AA; Omura GA; Gerber MC; Banks PL
    J Clin Oncol; 1992 Jul; 10(7):1103-11. PubMed ID: 1607916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Complete remission during administration of rhG-CSF in acute myeloblastic leukemia with pneumonia].
    Hayatsu K; Nagai K; Abe A; Murakawa E; Sekiya M
    Rinsho Ketsueki; 1994 Jan; 35(1):59-64. PubMed ID: 7511179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of etoposide added to individualized induction therapy of adult acute myeloid leukemia--the JALSG-AML-92 Study. Japan Adult Leukemia Study Group].
    Miyawaki S; Tanimoto M; Kobayashi T; Minami S; Tamura J; Omoto E; Kuriyama K; Hatake K; Saito K; Ohno R
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1160-7. PubMed ID: 10945011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length.
    Ohno R; Kato Y; Nagura E; Murase T; Okumura M; Yamada H; Ogura M; Minami S; Suzuki H; Morishima Y
    J Clin Oncol; 1986 Dec; 4(12):1740-7. PubMed ID: 3465875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
    Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson LE; Koller C; Kornblau S
    J Clin Oncol; 1994 Apr; 12(4):671-8. PubMed ID: 7512125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.